0001179110-22-003077.txt : 20220518
0001179110-22-003077.hdr.sgml : 20220518
20220518171228
ACCESSION NUMBER: 0001179110-22-003077
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220516
FILED AS OF DATE: 20220518
DATE AS OF CHANGE: 20220518
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SEVERINO MICHAEL
CENTRAL INDEX KEY: 0001609447
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35565
FILM NUMBER: 22940141
MAIL ADDRESS:
STREET 1: 1 N. WAUKEGAN ROAD
CITY: NORTH CHICAGO
STATE: IL
ZIP: 60064
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: AbbVie Inc.
CENTRAL INDEX KEY: 0001551152
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 320375147
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1 NORTH WAUKEGAN ROAD
CITY: NORTH CHICAGO
STATE: IL
ZIP: 60064
BUSINESS PHONE: (847) 932-7900
MAIL ADDRESS:
STREET 1: 1 NORTH WAUKEGAN ROAD
CITY: NORTH CHICAGO
STATE: IL
ZIP: 60064
4
1
edgar.xml
FORM 4 -
X0306
4
2022-05-16
0
0001551152
AbbVie Inc.
ABBV
0001609447
SEVERINO MICHAEL
1 N. WAUKEGAN ROAD
NORTH CHICAGO
IL
60064
0
1
0
0
Vice Chairman
Common Stock, $0.01 par value
2022-05-16
4
M
0
70879
61.36
A
222982
D
Common Stock, $0.01 par value
2022-05-16
4
M
0
29121
79.02
A
252103
D
Common Stock, $0.01 par value
2022-05-16
4
S
0
46273
154.04
D
205830
D
Common Stock, $0.01 par value
2022-05-16
4
S
0
53327
154.80
D
152503
D
Common Stock, $0.01 par value
2022-05-16
4
S
0
400
155.44
D
152103
D
Common Stock, $0.01 par value
2022-05-17
4
M
0
35364
79.02
A
187467
D
Common Stock, $0.01 par value
2022-05-17
4
M
0
64636
93.50
A
252103
D
Common Stock, $0.01 par value
2022-05-17
4
S
0
43621
153.43
D
208482
D
Common Stock, $0.01 par value
2022-05-17
4
S
0
54279
154.49
D
154203
D
Common Stock, $0.01 par value
2022-05-17
4
S
0
2100
155.27
D
152103
D
Option (Right to Buy)
61.36
2022-05-16
4
M
0
70879
61.36
D
2018-02-16
2027-02-15
Common Stock
70879
0
D
Option (Right to Buy)
79.02
2022-05-16
4
M
0
29121
79.2
D
2020-02-21
2029-02-20
Common Stock
29121
35364
D
Option (Right to Buy)
79.02
2022-05-17
4
M
0
35364
79.02
D
2020-02-21
2029-02-20
Common Stock
35364
0
D
Option (Right to Buy)
93.50
2022-05-17
4
M
0
64636
93.50
D
2021-02-20
2030-02-19
Common Stock
64636
49930
D
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.38 to $154.37 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.38 to $154.81 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at a price of $155.44. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.95 to $153.92 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $154.02 to $155.00 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at a price of $155.27. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.
The option exercise and sale transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).
Steven L. Scrogham, attorney-in-fact for Michael Severino
2022-05-18